Ranked on: #8 Largest Series A Rounds of 2026 (Ranked)
Is this your company? Get featured or correct your listing →
Recent changes
- Sep 9, 2026Sep 9, 2026Raised $225M Series A GlobeNewswire
- Sep 9, 2026Sep 9, 2026New investor: Canaan Partners GlobeNewswire
- Sep 9, 2026Sep 9, 2026New investor: RA Capital GlobeNewswire
- Sep 9, 2026Sep 9, 2026New investor: Forbion GlobeNewswire
- Sep 9, 2026Sep 9, 2026Solstice Oncology Launches With $225M Series A Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Sep 9, 2026 | Series A | $225M | — | GlobeNewswire |
Investors
Latest Pulse
- Sep 25, 2026Digital Health Quietly Has Its Best Year Since 2021Digital health raised $7.4 billion in H1 2026 after two lean years, and Pulse's own tracker shows the pace hasn't slowed since -- roughly $1.85 billion more across nine disclosed rounds in just the past 30 days.→
- Sep 11, 2026Newly Public Biotechs Are Already Back For More CashMapLight Therapeutics filed a $150 million follow-on just eleven months after its own IPO, part of a broader 2026 pattern of newly public biotechs returning to capital markets well ahead of their first pivotal data readouts.→
- Sep 9, 2026Solstice Oncology Launches With $225M Series ASolstice Oncology launched with a $225 million Series A led by RA Capital Management to advance porustobart, a second-generation CTLA-4 immunotherapy licensed from Harbour BioMed, into two Phase 2 cancer trials.→
Solstice Oncology FAQ
Who are Solstice Oncology's investors?
Solstice Oncology's investors include RA Capital, Canaan Partners, Forbion.
Sources & methodologyshow
Where these figures come from
- GlobeNewswireprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.